Necrotizing Fasciitis Market Research Report - Forecast till 2027

Necrotizing Fasciitis Market Trends And Share Analysis By Type (Type I, Type Ii, Type Iii), Treatment (Intravenous Antibiotics, Surgery, And Hyperbaric Oxygen Treatment), And End Users (Hospitals & Clinics, And Surgical Centers)- Forecast Till 2027

ID: MRFR/Pharma/4004-HCR | February 2021 | Region: Global | 203 pages

Necrotizing Fasciitis Market Scenario:


Also known as flesh-eating disease, necrotizing fasciitis is a rare bacterial infection affecting the tissue beneath the skin, surrounding muscles, and organs. The bacteria that is responsible for the disease releases toxins results into the damage nearby tissue. There are four major types for necrotizing fasciitis – type I known as polymicrobial infection, type II caused by haemolytic group A streptococcus, staphylococci such as methicillin resistant strains/MRSA, type III caused by bacterium such as clostridium, and others. It starts as a minor injury such as a small cut, but may get worst and can be life threatening if left untreated. Major risk factors for the disease are diabetes, cancer, obesity, intravenous drug use, alcoholism, and peripheral vascular disease. The disease can be prevented by maintaining hygiene which includes proper wound care and hand washing.


The necrotizing fasciitis market is majorly driven by the increasing prevalence of cancer, diabetes, continuously increasing geriatric population and increasing number of patients suffering from various bacterial infection. However, the growth of the necrotizing fasciitis market is restricted due to lack of awareness about necrotizing fasciitis and high cost of treatment.


The necrotizing fasciitis market is expected to grow at a CAGR of 6.2% during the forecasted period.


Figure: Global Necrotizing Fasciitis Market, by Region, 2016 (%)


 Necrotizing Fasciitis Market


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, market research future analysis, annual report, white paper, company presentation


Research Methodology:


 Necrotizing Fasciitis


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, market research future analysis, annual report, white paper, company presentation


Segments 



  • The necrotizing fasciitis market is segmented on the basis of type, treatment, and end users.



  • On the basis of the type, the necrotizing fasciitis market is categorized into Type I, Type II, Type III and others.



  • On the basis of the treatment, the necrotizing fasciitis market is segmented into intravenous antibiotics, surgery, hyperbaric oxygen treatment and others.



  • On the basis of the end users, the market is segmented into hospitals & clinics, surgical centers and others.


Regional Analysis


America accounts for the largest share in the necrotizing fasciitis market owing to presence of key players in the necrotizing fasciitis market and rising emphasis on diagnosis and treatment of rare diseases. Furthermore, rising awareness about bacterial infection is further set to accelerate the growth of the necrotizing fasciitis market. North America is the accounted for the highest market share in this region with the U.S. being the largest market followed by Canada. In the U.S, the prevalence of cardiovascular disease is found to be increasing from last few years. This is attributed to the rising prevalence of chronic diseases such as obesity and diabetes which are the major risk factors for cardiovascular diseases. As per the Center for Disease Control & Prevention (CDC), in 2015, 28.4 million adults were diagnosed with cardiovascular diseases in the U.S. alone.


Europe is the second largest market and holds a noticeable share in the necrotizing fasciitis market. The European market is expected to grow significantly during the forecast period owing to availability of advanced treatment facilities and skilled medical professionals. Furthermore, extensive research and development activities for the treatment of rare disease and increasing government support.


Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes, cancer and bacterial infection in developing countries is the major driver for the market growth. China and India are the fastest growing regions owing to increasing geriatric population. Also, the diabetes is one of the major chronic conditions affecting large number of patients, thereby influencing the market growth. Rising awareness about the infections and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drive the market. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, which is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India, respectively. It stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the population had hypertension


The Middle East & Africa is expected to show the least growth in the necrotizing fasciitis market due to some major factors such as lack of awareness about necrotizing fasciitis, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates holds the largest market share owing to development of healthcare industry and rising availability of specialty care centers.


Key Players


Some of the key players in necrotizing fasciitis market are Merck & Co. (U.S.), WOCKHARDT (India), Atox Bio (Israel), Teva Pharmaceutical Industries (Israel), Basilea Pharmaceutica Ltd. (Switzerland), and MELINTA THERAPEUTICS, INC. (U.S.)

Intended Audience



  • Pharmaceutical manufacturers and suppliers

  • Medical research laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   6.2% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, and End users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Merck & Co. (U.S.), WOCKHARDT (India), Atox Bio (Israel), Teva Pharmaceutical Industries (Israel), Basilea Pharmaceutica Ltd. (Switzerland), and MELINTA THERAPEUTICS, INC. (U.S.)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of cancer, diabetes, continuously
  • Increasing geriatric population
  • Increasing number of patients suffering from various bacterial infection


  • Frequently Asked Questions (FAQ) :


    Necrotizing fasciitis market is expected to expand at 6.2% CAGR from 2017 to 2023.

    Necrotizing fasciitis market is driven by large number of patients affected by bacterial infections, large geriatric populace, and prevalence of non-communicable diseases.

    Necrotizing fasciitis market is restrained by lack of awareness of the disease.

    APAC can display a robust growth rate in the necrotizing fasciitis market.

    WOCKHARDT, MELINTA THERAPEUTICS, INC. Basilea Pharmaceutica Ltd., Teva Pharmaceutical Industries, Merck & Co., and Atox Bio are key players of the necrotizing fasciitis market.